Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients

Yoshida, Yoichiro; Hoshino, Seiichiro; Aisu, Naoya; Naito, Masayasu; Tanimura, Syu; Mogi, Ai; Tanaka, Toshihiro; Hirata, Keiji; Tamura, Kazuo; Yamashita, Yuichi

doi:10.1007/s10147-014-0703-5

Cited by 24 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously reported port-free chemotherapy administration via the median cubital vein for CRC and showed that the resulting low complication rates helped to ensure completion of chemotherapy without delay for most patients (Yoshida et al 2012, b). However, VP occasionally necessitates changing an oxaliplatin drip infusion to a peripheral vein during XELOX therapy.…”

Section: Discussionmentioning

confidence: 99%

“…A total of 58 patients with metastatic CRC who underwent XELOX plus bevacizumab therapy (7.5 mg/kg bevacizumab and 130 mg/m 2 oxaliplatin on day 1 plus 2000 mg/m 2 capecitabine on days 1–14, repeated every 3 weeks) or XELOX therapy (130 mg/m 2 oxaliplatin on day 1 plus 2000 mg/m 2 capecitabine on days 1–14, repeated every 3 weeks) (Yoshida et al 2015a, b) at Fukuoka University Hospital between April and August 2014 were included in this study.…”

Section: Methodsmentioning

confidence: 99%

“…Recently developed therapies combining capecitabine plus oxaliplatin (XELOX) allow for chemotherapy via a peripheral vein without CV port (Yoshida et al 2015b). However, vascular pain (VP) occasionally necessitates the movement of oxaliplatin drip infusions to a peripheral vein during XELOX therapy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Objective evaluation of oxaliplatin-induced vascular pain secondary to peripheral vein administration

et al. 2016

Self Cite

View full text Add to dashboard Cite

BackgroundDuring oxaliplatin chemotherapy administration via a peripheral vein, vascular pain requires changing of the intravenous infusion route on occasion. Vascular pain induced by anticancer drugs reduces the rate of patient continuation and completion of chemotherapy. Pain is presently appraised using subjective methods, such as the visual analog scale (VAS). However, because pain evaluation can vary depending on the physical state and mood of the patient at the time of assessment, it is desirable to evaluate pain objectively. PainVision PS-2100 (PV) is a medical device that was designed to objectively and quantitatively assess patient nociception and perception.MethodsThe present study examined the correlation of subjective and objective assessment of oxaliplatin-induced vascular pain using VAS and PV, respectively.ResultsVascular pain was assessed using both PV and VAS a total of 173 times for 58 colorectal cancer patients. Partial correlation analysis was performed to evaluate the relationship between PV and VAS. The mean PV and VAS scores were 44.5 (range: 0–596) and 24.8 (range: 0–100), respectively. The partial correlation coefficient was 0.408 (p < 0.0001).ConclusionsA strong correlation was not observed between the results, and a weak correlation was observed between VAS and PV scores. Objective evaluation of oxaliplatin-induced vascular pain will be required to help patients overcome vascular pain.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Objective evaluation of oxaliplatin-induced vascular pain secondary to peripheral vein administration

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…KRAS codon 12 showed TGT mutation. We started XELOX + bevacizumab therapy (BV [7.5 mg/kg] and oxaliplatin [130 mg/m 2 ] on day 1 plus capecitabine [1,000 mg/m 2 ] twice daily on days 1–14, every 3 weeks) as a first-line treatment [3] and then started IRIS + bevacizumab therapy (BV [7.5 mg/kg] and irinotecan [150 mg/m 2 ] on day 1 plus S-1 [80 mg/m 2 ] twice daily on days 1–14, every 3 weeks) as a second-line treatment [4]. Prior to chemotherapy, the renal, hepatic, and bone marrow functions were almost normal.…”

Section: Case Reportmentioning

confidence: 99%

Difference in Neutropenia due to Administration Schedule of TAS-102

et al. 2017

Self Cite

View full text Add to dashboard Cite

TAS-102 significantly improves overall survival in patients with metastatic colorectal cancer. The most common adverse event of TAS-102 is bone marrow suppression, which leads to neutropenia. The incidence of neutropenia is high, and there is no known effective prevention method. Furthermore, the administration method of TAS-102 is complicated. We reported that neutropenia could be avoided by changing to a simple administration method of TAS-102.

show abstract

“…Patients underwent XELOX therapy (130 mg/m 2 oxaliplatin on day 1+1000 mg/m 2 capecitabine twice daily on days 1‐14) on postoperative day 7 and XELOX+bevacizumab (7.5 mg/kg bevacizumab and 130 mg/m 2 oxaliplatin on day 1+1000 mg/m 2 capecitabine twice daily on days 1‐14, every 3 weeks) after the second chemotherapy cycle 13, 14. Dose reductions were required for all grade 3 or 4 toxicities that were attributed to the study medications.…”

Section: Methodsmentioning

confidence: 99%

Phase II study on early start of chemotherapy after excising primary colorectal cancer with distant metastases (Pearl Star 02)

Yoshida

Aisu

Kojima

et al. 2017

Annals of Gastroent Surgery

Self Cite

View full text Add to dashboard Cite

Initiating chemotherapy usually requires a delay of more than 4 weeks after surgically resecting colorectal cancer. However, there is little evidence regarding the required delay interval. We have previously reported a pilot study to determine the safety and feasibility of early initiation of chemotherapy after resecting primary colorectal cancer with distant metastases. We aimed to determine the safety and efficacy of early initiation of chemotherapy after resecting colorectal cancer with distant metastases.This phase II study (trial number UMIN000006310) was a prospective, single‐arm trial. A total of 20 patients (men, 15 and women, 5) were enrolled. They underwent XELOX therapy (130 mg/m2 oxaliplatin on day 1+1000 mg/m2 capecitabine twice daily on days 1‐4) on postoperative day 7 and XELOX+bevacizumab (7.5 mg/kg bevacizumab on day 1) after the second chemotherapy cycle.Baseline characteristics included a median age of 64 (range, 43‐72) years. Surgical procedures included right hemicolectomy in six patients, sigmoidectomy in three, anterior resection in five, and Hartmann procedure in six. All patients started chemotherapy on postoperative day 7. Median progression‐free survival was 14.9 months; overall response rate was 80%. Disease control rate was 100%. Grade 3 or higher hemotoxicity and grade 3 or higher non‐hematological toxicity was noted in 5.0% and 25.0% of patients, respectively. Postoperative complications were observed in two patients (superficial incisional surgical site infection and ileus).Early initiation of chemotherapy after surgery is feasible. These findings suggest future changes of the start time of chemotherapy after surgery.

show abstract

Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients

Abstract: Port-free-chemotherapy administration via the median cubital vein is appropriate for patients with colorectal cancer, thereby avoiding complications associated with CV-ports.

Cited by 24 publications

References 31 publications

Objective evaluation of oxaliplatin-induced vascular pain secondary to peripheral vein administration

Objective evaluation of oxaliplatin-induced vascular pain secondary to peripheral vein administration

Difference in Neutropenia due to Administration Schedule of TAS-102

Phase II study on early start of chemotherapy after excising primary colorectal cancer with distant metastases (Pearl Star 02)

Contact Info

Product

Resources

About